Stephen Dorton - Enfusion Chief Officer
ENFNDelisted Stock | USD 10.76 0.00 0.00% |
Insider
Stephen Dorton is Chief Officer of Enfusion
Age | 58 |
Phone | 312 253 9800 |
Web | https://www.enfusion.com |
Enfusion Management Efficiency
The company has return on total asset (ROA) of 0.0305 % which means that it generated a profit of $0.0305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0442 %, meaning that it created $0.0442 on every $100 dollars invested by stockholders. Enfusion's management efficiency ratios could be used to measure how well Enfusion manages its routine affairs as well as how well it operates its assets and liabilities.Enfusion currently holds 20.31 M in liabilities. Enfusion has a current ratio of 8.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Enfusion's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Showing other executives | INSIDER Age | ||
A Rohde | Meridianlink | 39 | |
Susan Ganeshan | Clearwater Analytics Holdings | 53 | |
Kent Radford | CS Disco LLC | 53 | |
James Cox | Clearwater Analytics Holdings | 53 | |
Aaron Clark | CS Disco LLC | 38 | |
Martin Simoncic | PROS Holdings | 42 | |
Martin Fichtner | E2open Parent Holdings | N/A | |
Pradeep Rathinam | Freshworks | 53 | |
Alex Saleh | ON24 Inc | N/A | |
Leo Ryan | ON24 Inc | N/A | |
Srinivasagopalan Ramamurthy | Freshworks | 58 | |
Scott Hill | CS Disco LLC | 57 | |
Keith Abell | E2open Parent Holdings | 63 | |
Lee Robinson | CS Disco LLC | N/A | |
Stephen Daffron | E2open Parent Holdings | 64 | |
Raja Hammoud | PROS Holdings | 49 | |
Byron Bardy | ON24 Inc | N/A | |
Nate Pollack | ON24 Inc | N/A | |
Charles Longfield | Blackbaud | 67 | |
Nikki Brewer | PROS Holdings | 43 | |
Sean Blitchok | Meridianlink | 50 |
Management Performance
Return On Equity | 0.0442 | |||
Return On Asset | 0.0305 |
Enfusion Leadership Team
Elected by the shareholders, the Enfusion's board of directors comprises two types of representatives: Enfusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enfusion. The board's role is to monitor Enfusion's management team and ensure that shareholders' interests are well served. Enfusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enfusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
Stephen Dorton, Chief Officer | ||
Michael Berry, Chief Officer | ||
Lorelei Skillman, Chief Officer | ||
Vivek Ranka, Head Technology | ||
Stephen Malherbe, Managing Partner | ||
Oleg Movchan, Interim Director | ||
Matthew Campobasso, General Secretary | ||
Bronwen Bastone, Chief Officer | ||
Joseph Defeo, Global Production | ||
Lotte Tonsberg, Head EMEA | ||
Kabir Kohli, MD Services | ||
Jeff Young, Head Implementation | ||
Iris Wang, Chief Officer | ||
Brian Murphy, Investor | ||
Matt Campobasso, General Counsel | ||
Robert Taylor, Head Support | ||
Ignatius Njoku, Head Relations | ||
Bradley Herring, Chief Officer | ||
Neal Pawar, Chief Officer | ||
Daniel Groman, Chief Officer | ||
Valeria Gutowski, Chief Officer |
Enfusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enfusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0442 | |||
Return On Asset | 0.0305 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.03 % | |||
Current Valuation | 1.01 B | |||
Shares Outstanding | 94.8 M | |||
Shares Owned By Insiders | 4.73 % | |||
Shares Owned By Institutions | 96.25 % | |||
Number Of Shares Shorted | 1.3 M | |||
Price To Earning | 0.11 X |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Enfusion Stock
If you are still planning to invest in Enfusion check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enfusion's history and understand the potential risks before investing.
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
CEOs Directory Screen CEOs from public companies around the world | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |